A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Clinical trial NCT06051695 · RECRUITING

Trial details

NCT number: NCT06051695
Sponsor: A2 Biotherapeutics Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor, Adult Colorectal Cancer NSCLC Non Small Cell Lung Cancer NSCLC, Recurrent Non-Small Cell Squamous Lung Cancer Pancreas Cancer Pancreatic Neoplasm Colorectal Adenocarcinoma CRC Colon Cancer Rectal Cancer

Start date: 2024-04-03
Primary completion: 2028-06-01
Enrollment: 474

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.